The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX ®. Abera is a developer of mucosal vaccines and has several preclinical ...

The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations ...

Abera Bioscience and Orexo have entered a partnership to develop and test the powder formulations of the former’s vaccine candidates against influenza, leveraging Orexo's AmorphOX technology. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Orexo AB (publ.), a Swedish pharmaceutical company, announced that it continues to develop its innovative powder-based drug delivery technology AmorphOX to improve the properties of new or existing ...